Medicines & Healthcare products Regulatory Agency

NIBSC

DATA SHEET

REAGENT	Plasma from HIV-1 infected patient (EUR 0075)
REAGENT ID	100053
LOT NUMBER	N/
DESCRIPTION	Plasma from HIV-1 infected patient
ORIGIN	Brazil
SUBTYPE	F1 (PRT and V3)
SEQUENCE	Genbank accession number: KU685571 (PRT); KU685551 (V3))

CHARACTERISTICS

YEAR OF DIAGNOSIS	CLINICAL STAGE	GENDER	AGE	RISK FACTOR
2014	Newly diagnosed	F	39	Heterosexual

GENOTYPIC PREDICTION OF CCRR USAGE	RESISTANCE TO RTIs	NRTIs RESISTANCE MUTATIONS	NNRTIs RESISTANCE MUTATIONS	RESISTANCE TO PIs	PIs RESISTANCE MUTATIONS
R5	NO	None	V106I	NO	L10V

VIROLOGICAL/IMMUNOLOGICAL DATA

CD4	VIRAL LOAD (copies/ml)
733	2940

PROVIDED	200µl of plasma
STORAGE	- 80 °C
CONTRIBUTOR	Miguel Thomson and Lucia Pérez Álvarez, HIV Biology and Variability Unit, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain
ACKNOWLEDGMENTS	Acknowledgment for publications should read "The following reagent was obtained from the Centre for Infectious Disease Reagents, MHRA, UK: Plasma from HIV-1 infected patient (EUR 0075, NIBSC #100053), thanks to the contribution of Miguel Thomson and Lucia Perez Alvarez at the HIV Biology and Variability Unit, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain".

Medicines & Healthcare products Regulatory Agency

NIBSC

MATERIAL SAFETY SHEET

Physical properties (at room temperature)			
Physical appearance	Plasma, frozen liquid		
Fire hazard	None		
Chemical properties			
Stable	Yes	Corrosive:	No
Hygroscopic	No	Oxidising:	No
Flammable	No	Irritant:	No
Other: **Infectious HIV-1 (HG3)**. It is the responsibility of the end user to seek local biosafety approval for the storage and handling of the material in their workplace			
Handling: CAUTION - This preparation is not for administration to humans or animals in the human food chain. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include using the sample in the correct containment facility, the wearing of protective gloves and avoiding the generation of aerosols.			
Toxicological properties			
Effects of inhalation:	Risk of HIV-1 infection, avoid inhalation		
Effects of ingestion:	Risk of HIV-1 infection, avoid ingestion		
Effects of skin absorption:	Risk of HIV-1 infection, avoid contact with skin		
Suggested First Aid			
Inhalation	Seek medical advice		
Ingestion	Seek medical advice		
Contact with eyes	Wash with copious amounts of water. Seek medical advice.		
Contact with skin	Wash thoroughly with soap and water.		
Action on Spillage and Method of Disposal			
Spillage of contents should be taken up with absorbent material wetted with an appropriate virucidal agent. Rinse area with an appropriate virucidal agent followed by water. Absorbent materials used to treat spillage should be treated as biologically hazardous waste.			